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ABSTRACT
The homeostatic controls over eating are
inextricably linked to the reward aspects of
eating. The result is an integrated response that
coordinates the internal milieu with the
prevailing environment. Thus, appetite, which
reflects a complex interaction among the
external environment, behavioral profile, and
subjective states as well as the storage and
metabolism of energy, has an important role
in the regulation of energy balance. In the
prevailing food environment which offers an
abundance of food choices it is likely that the
motivation to consume from a wide range of
delectable foods plays a greater role in
contributing to overeating than in the past
when the motivation to eat was largely
governed by metabolic need. The response to
food-related cues can promote strong desires to
eat known as cravings by activating the
mesocorticolimbic dopamine neurocircuitry.
Cravings are associated with subsequent eating
and weight-related outcomes. Being able to
control food cravings is a determinant of
success at adhering to an energy-restricted diet
regimen. Increased understanding of the
neurocircuitry of appetite regulation,
especially reward-related eating behavior, has
provided potential targets for therapeutic
anti-obesity agents specifically directed
at reward mechanisms. The
naltrexone–bupropion combination and
lorcaserin, which are both approved by the US
Food and Drug Administration (FDA) for
long-term weight management, have shown
promise in addressing craving-related eating
behavior. Phentermine and liraglutide are
approved as monotherapies for weight
management. Preliminary research suggests
that liraglutide, as well as phentermine alone
or in combination with lorcaserin, may be
effective in targeting food cravings. Food
components such as thylakoid membranes
have also been shown to influence food
cravings. This review explores the concepts
related to appetite and reward-induced eating
behavior, as well as the pharmacological
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options and food-derived components that may
be used to address food cravings.
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INTRODUCTION
Globally, the leading causes of death are
cardiovascular disease (CVD), especially
coronary heart disease and stroke [1].
Overweight and obesity are important risk
factors of CVD [2–4], operating in part
through mechanisms such as elevated levels of
blood pressure, dyslipidemia, and abnormal
glucose metabolism. However, interventions
that address these abnormalities resolve
approximately half of the excess risk for
coronary heart disease that may be attributed
to a high body mass index [5]. Thus,
maintenance of optimum body weight
through strategies that can curb or reverse
adiposity is of paramount importance in
reducing CVD and type 2 diabetes [5].
Current obesity guidelines suggest that
sustained weight loss of just 3–5% achieved
through lifestyle interventions can result in
clinically significant positive metabolic
outcomes [2]. Any obesity treatment involves
creating a negative energy balance. Finding the
optimal diet composition for achieving a
negative energy balance has proven elusive.
What appears to be important is not the type of
diet, but adherence to a diet regimen that
promotes energy restriction [6]. Lifestyle
change programs can help many individuals to
achieve weight loss but a large percentage will
fail to do so and many of those who achieve it
will regain body weight. Weight loss induces
neuroendocrine changes that impinge on what
is called ‘‘willpower’’, as a result of
counter-regulatory mechanisms that provoke a
powerful unconscious impulse to eat [7]. There
are associated increases in neural activity in
areas of the brain involved in processing the
rewarding value of food stimuli [8, 9].
Economic growth and technological
developments are important for prosperity, but
the trade-off to business and trade by way of less
regulated global markets has led to the creation
of cheap, easily available food sources [10]. The
biological drive to eat is inextricably linked not
only to the satiating and satiety-enhancing
power of food but also to its rewarding value.
In an environment that presents a plethora of
inviting food choices the consumer is often
prodded to disregard dietary recommendations
[11]. Obesity results from a chronic energy
imbalance; hence, controlling the urge to eat
assumes importance. This review explores the
concepts related to appetite regulation with
special emphasis on reward-induced eating and
interventions that target reward mechanisms.
Compliance with Ethics Guidelines
This article is based on previously conducted
studies and does not involve any new studies of
human or animal subjects performed by any of
the authors.
APPETITE
Appetite reflects a complex interaction between
the external environment, the behavioral
profile, and subjective states as well as the
storage and metabolism of energy [12]. The
expression of appetite manifests the interplay of
events and processes that occur at three levels:
(1) psychological events such as perceptions of
hunger, food cravings, or hedonic sensations,
and the corresponding behavioral actions; (2)
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responses in the peripheral physiologic system
and metabolic events which stem from nutrient
absorption, metabolism, and storage; and (3)
central neural processes that translate the
physiologic events [13].
The hypothalamus is the cerebral appetite
center, integrating peripheral humoral signals
that transmit information about food intake and
energy expenditure with neuronal signals from
the brainstem and higher cortical center dealing
with cognition, pleasure, and emotion [14].
Within the arcuate nucleus of the
hypothalamus there are two neuronal
populations with opposing effects on food
intake. The neurons which co-express
neuropeptide Y and agouti-related peptide
(AgRP) increase appetite, whereas the neurons
that co-express the cocaine- and
amphetamine-regulated transcript (CART) and
proopiomelanocortin (POMC) decrease appetite,
by acting on the melanocortin-4 receptor
(MC-4R). Proopiomelanocortin cells produce
a-melanocyte stimulating hormone (a-MSH) an
MC-4R agonist, whereas AgRP is an MC-4R
antagonist [15, 16]. Following the ingestion of
food, sensory information is transmitted from
the gastrointestinal tract to the central nervous
system either through vagal and somatosensory
afferent fibers or via bloodstream signals which
maybe theguthormones [17]. Thepresenceof an
incomplete blood–brain barrier in the regions of
the brain such as the area postrema permit many
circulating signals, including the gut hormones,
direct access to the central nervous system [18].
Thus, complex neuronal pathways with
reciprocal connections between the
hypothalamus, brainstem, and higher cortical
areas [19] are involved in the control of appetite
acting through endocrine andneuronal feedback
signals from the periphery to synchronize
appetite perception, food intake behavior, and
energy homeostasis.
The widely accepted homeostatic view of the
control of food intake is that adiposity signals
such as leptin and insulin influence the
sensitivity to meal-derived satiation signals to
regulate meal size in response to changes in
body weight [20]. Energy homeostasis is
coordinated by two sets of signals. Long-term
or tonic signals emanate from tissue stores,
predominantly adipose, and include chemical
signals such as leptin, insulin, adiponectin, and
certain cytokines. Short-term or episodic signals
are generated periodically as food intake occurs
and for the most part arise in the
gastrointestinal tract. Some of the chemical
components of episodic signals are
cholecystokinin (CCK), peptide YY (PYY),
glucagon-like peptide-1 (GLP-1), ghrelin, and
oxyntomodulin released from cells in and
around the gastrointestinal tract. Cerebral
integration of tonic and episodic signals
reflects the current state of energy stores and
the flux of nutrients prompted by an eating
episode [21].
Translation of the metabolic need into
behavioral action is closely intertwined with
reward and is orchestrated by a cognitive and
emotional brain that operates on factors such as
past experiences, cost, and availability [22]. The
mesocorticolimbic system is involved in reward
processing through dopamine release from
neurons in the ventral tegmental area and
their projections to the nucleus acumbens,
amygdala, prefrontal complex, and other
forebrain regions [23]. In the reward system,
dopamine and opioid systems interact in the
determination of eating behavior [24].
Dopamine signaling plays an important role in
translating motivation into action [25], and
increases the drive to obtain a rewarding
stimulus, but it is opioid peptide transmission
in the nucleus acumbens rather than dopamine
that modulates the hedonic or pleasure impact
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of food [23, 26] (Fig. 1). Specifically, opioids,
particularly the l-opioids, covey the reward
sensation of desirable foods whereas dopamine
regulates the reward value of food and the
motivation to obtain that food [27]. Thus,
appetite reflects (1) physiologic hunger or a
conscious sensation reflecting an urge to eat
and (2) reward that can be triggered without




In the modern world, humans often eat in the
absence of any metabolic feedback indicating a
diminution of reserves [22]. This
non-homeostatic eating involves perceptions
of food reward. The psychological components
of reward include (1) learning which includes
knowledge resulting from associative and
cognitive processes; (2) affect (emotion) or
liking which reflects the immediate experience
or eagerness to experience pleasure from the
hedonic value of consuming a food; and (3)
motivation to actually eat, or wanting [28].
Components of affective and motivational
processes can exist objectively, without
conscious awareness of them. Therefore, they
can be implicit which assumes importance
because individuals can react to a rewarding
stimulus without conscious awareness of either
the stimulus or their hedonic response to it [28].
Perceptions of food reward can occur by
encountering food-related cues such as the
sight, smell, and taste of the food, sensations
that often initiate an intense desire to eat
known as craving: a conditioned response to
food that is often accompanied by increased
salivation, physiologic arousal, and neural
stimulation. Such craving is a form of food cue
reactivity, called cue-induced craving. Another
type of craving that arises independently of
external cues as may occur when merely
imagining a favorite food causes the individual
to be consumed with the desire to eat and is
known as tonic craving. Other forms of craving
include state craving which is tonic or
cue-related craving assessed at a particular
moment in time and trait craving which is a
general tendency to crave with or without the
presence of cues [29]. Further, there are gender
differences in cravings and the response to
Fig. 1 Brain reward circuitry. a Neurons in the VTA of
the midbrain project to forebrain areas including the NAc,
striatum, and cortex, and assign reward value to
palatable food. b Perception of pleasure associated with
consumption of a palatable food involves neuronal
activation in the NAc and striatum, which through
activation of opiate peptide receptors disinhibits the lateral
hypothalamic area and thereby stimulates feeding. Amy
amygdala, GP globus pallidus, NAc nucleus accumbens,
VTA ventral tegmental area. Reprinted with permission
from Macmillan Publishers: Morton et al. [26]
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them. Men exhibit a yearning for savory foods
[8, 30, 31], whereas women prefer high-fat
sweet foods such as chocolate [8, 31, 32].
Women have a greater inclination than men
to succumb to cue-related food cravings, and
more so in the luteal phase of the menstrual
cycle [29].
Both cue-related and tonic craving are
associated with subsequent eating and
weight-related outcomes. Moreover, reactivity
to visual cues such as images of food is as related
to eating behavior as real food [33]. Individuals
unsuccessful at adhering to dietary energy
restriction report greater food cravings that are
related to loss of control over eating and plans
to consume food than those who achieve
success at following a diet regimen [34].
Meta-analyses of brain imaging studies suggest
that major brain regions involved in cue
reactivity to alcohol, drugs of abuse, sex,
gambling, smoking, and food for the most part
overlap, and consist of a network that processes
reward responses [35, 36]. These biological and
behavioral parallels suggest that eating behavior
is addictive. It appears that food cravings are a
mediator between addictive eating behavior
and increases in body weight [37].
Hypothalamic signals regulating energy
intake can influence the activity of the
hedonic or reward systems in the corticolimbic
structures [38]. Similarly, signals generated in
the corticolimbic structures processing reward
information can modulate hypothalamic
processes involved in homeostatic control [39].
The result is a complex integration of multiple
interacting neuronal circuits and a number of
factors that strengthen, attenuate, or override
others. For instance, food deprivation exerts a
stimulatory effect on reward perception. The
proposed mechanism is that leptin and insulin
tonically inhibit the reward circuitry in the
brain, and energy restriction by lowering
circulating levels of these hormones increases
the responses to rewarding stimuli as an
adaptive mechanism to prevent drastic
depletion of body stores [26]. Conversely,
circulating levels of the hormone ghrelin are
elevated during fasting and fall after eating,
suggesting that ghrelin exerts an orexigenic
effect to stimulate hunger. Ghrelin also
modulates both liking and wanting aspects of
reward-driven eating and increases the
motivation to obtain and consume foods in
part by activating dopaminergic neurons in the
ventral tegmental area and stimulating
dopamine release within the nucleus
acumbens [40].
Obesity trends suggest that overriding of
homeostatic control by corticolimbic processes
may be the cause of energy imbalance; however,
it remains debatable as towhether the short-term
regulation of food intake can truly be called a
homeostatic response if the correction of
imbalances is not critical [20]. Thus, targeting
perceptions of food reward can have significant
implications for publichealth initiatives directed
at reducing energy intake [41].
MEASURING REWARD-DRIVEN
APPETITE
To evaluate the intensity and type of food
cravings an individual experiences, the Control
of Eating Questionnaire (COEQ) has often been
used [42–44]. In a recent validation study, loss
of control due to cravings and a positive mood
were associated with increased total energy
intake at an ad libitum snack service. Further,
the craving for sweet was strongly associated
with intake and selection of sweet foods.
However, the craving for savory foods did not
show the same association which may reflect
differences between choices at main meals and
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snacks [42]. The Food Craving Inventory (FCI)
has also been shown to be a valid and reliable
measure of general and specific food cravings
[45]. Both of these questionnaires appear to
converge with data from psychometric tests
such as the Eating Inventory which measures
traits (predispositions exhibited by an
individual that are relatively stable across
time) related to eating behavior [46]. The State
and Trait Food Craving Questionnaires are
validated means of measuring state and trait
cravings [47, 48]. The Yale Food Addiction scale
is a measure of addictive-like eating behaviors
that has been validated to various extents across
different age groups, races, and among subjects
with obesity or eating disorders. However, the
concept of food addiction has been criticized
because of the lack of evidence for
substance-based food addiction [49].
Neuroimaging using functional magnetic
resonance imaging to permit measuring and
mapping of brain activity that is specific to food
stimuli in the reward circuitry is also a possible
way to measure motivational signals [50, 51].
TARGETING REWARD
MECHANISMS
The term obesity was paired with each of the
following terms using the operator AND: food
cues, food cravings, and reward-induced eating.
The paired terms were used to perform a
literature search on PubMed. Six human
intervention trials investigating the effects of
medications approved by the US Food and Drug
Administration (FDA) for weight management
on reward-induced eating and three human
trials investigating the effect of a food-derived
component on reward-related mechanisms
were identified for the period ending August
31, 2016. Additionally, one medication-related
trial Moldovan et al. was identified through a
personal communication. The results of the
PETAL study [52, 53], a trial relating to food
cravings, were presented at the meeting of the
Obesity Society, 2015.
Pharmacologic Interventions
Anti-obesity medications are approved for
individuals with a BMI of at least 30 kg/m2 or
a BMI of at least 27 kg/m2 having at least one
obesity-related co-morbidity. The combination
of naltrexone extended release (ER) and
bupropion ER (ContraveTM) is approved by the
FDA for long-term weight management in
patients with obesity [54]. Naltrexone and
bupropion are approved by the FDA as
monotherapies for other conditions.
Bupropion, a dopamine reuptake inhibitor, is
approved for the treatment of depression and
seasonal affective disorder, and to aid in
smoking cessation [55, 56]; whereas,
naltrexone, an opioid receptor antagonist, is
approved for the treatment of alcohol and
opioid dependence [57, 58]. Bupropion is
thought to stimulate secretion of a-MSH from
POMC cells which produces an anorexic effect.
Further, the antidepressant effects of bupropion
and its effectiveness in aiding smoking
cessation suggest that it mediates processes in
the reward system [59]. Although bupropion
stimulates POMC activity, the anorexic effects
of POMC are curtailed by the melanocortin
system’s inherent feedback mechanism that
limits sustained stimulation of POMC cells by
simultaneous secretion of endogenous opioids
such as b-endorphins that inhibit a-MSH
secretion [27].
Naltrexone monotherapy has little efficacy
for weight management. However, consistent
with the established role of opiates in the
reward aspects of eating and stimulation of
1858 Adv Ther (2016) 33:1853–1866
consumption of energy dense sugar and
fat-laden foods [60], naltrexone antagonism of
opioid receptors reduces the subjective
pleasantness or liking of certain foods [61, 62].
Blockade of the l-opioid receptor with
naltrexone to counteract the auto-inhibitory
actions of bupropion-stimulated release of
endogenous opioids forms the basis of the
combination treatment of bupropion and
naltrexone for obesity treatment. Moreover,
naltrexone and bupropion both reduce food
intake in mice when injected directly into the
reward system; but the effect is synergistic when
they are administered together. Results from the
phase III trials showed that the combination
treatment of naltrexone and bupropion
consistently reduced measures of food reward
assessed using the COEQ [43, 44, 63]. Subjects
reported reduced frequency and strength of
food cravings (Table 1).
Phentermine (common brand names
Adipex-PTM, IonaminTM) is primarily a
noradrenergic and perhaps dopaminergic
sympathomimetic amine that acts as an
appetite suppressant [64]. It was approved by
the FDA for use in conjunction with lifestyle
change efforts for short-term (few weeks) weight
management [65]. A 12-week randomized
controlled trial evaluated the effect of
phentermine and a meal replacement system
along with nutritional counseling on weight
loss and food cravings. A greater proportion of
subjects in the phentermine group achieved
weight loss of 5% or more, and the craving for
fats and sweets (evaluated using the Trait and
State Food Cravings Questionnaires) was
reduced in the phentermine group, compared
to the group receiving the meal replacement
and counseling along with a placebo. Further,
the reduction in craving positively correlated
with weight loss over the 12-week period [66].
Serotonin (5-hydroxytryptamine, 5-HT) is a
neurotransmitter that regulates food intake and
energy expenditure by acting on the central
nervous system, with the key mediators being
the 5-HT2C receptors (5-HT2CR) [67]. Agonists
of 5-HT2CR activate POMC neurons which
results in the release of a-MSH and activation
of the anorexigenic central melanocortin
pathway through MC-4R [68–70]. Lorcaserin
(BelviqTM) is a highly specific 5-HT2CR
approved by the FDA for the long-term
treatment of obesity [71]. Studies showed that
lorcaserin produced weight loss without the
adverse cardiac outcomes associated with
non-specific serotonin receptor agonists
Table 1 Therapies for reducing reward-related eating
Therapy Effect References
Naltrexone ? bupropion (ContraveTM) Reduces frequency and strength of food cravings [43, 44, 63]
Phentermine (Adipex-PTM, IonaminTM)a Suppresses appetite [66]
Lorcaserin (BelviqTM) Improves facets of inhibitory control [79–81]
Lorcaserin ? phentermine Reduces frequency and strength of food cravings.
Reduces cravings for high-fat foods, sweets, fast foods
[52, 53]
Liraglutide (SaxendaTM) Reduces attention to food cues [82, 88]
Thylakoid membranes (AppethylTM) Reduces desire for sweet foods and chocolate [93, 94]
a Some common brand names
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[72–74]. The role of 5-HT2CR in the regulation
of forebrain dopaminergic systems is well
established [75–77], suggesting that agonists of
5-HT2CR should affect behaviors motivated by
food [78]. On the basis of research in substance
abuse, it appears that agonists of 5-HT2CR
including lorcaserin improve facets of
inhibitory control, which has the potential to
prevent relapse following a period of abstinence
[78–81]. Given the neurobiological and
behavioral commonalities between obesity and
drug addiction, it is not surprising that
lorcaserin has been investigated for its effects
on food cravings.
In the Pilot Evaluation of Tolerability and
Safety of Lorcaserin and phentermine (PETAL)
study, conducted to evaluate if administration
of the combination of lorcaserin with
immediate release phentermine for 12 weeks
was associated with adverse events, the effect of
the drug administration on food cravings was
also evaluated as a secondary endpoint.
Subjects were given lorcaserin 10 mg twice
daily or lorcaserin 10 mg twice ? phentermine
15 mg once daily, or lorcaserin 10 mg
twice ? phentermine 15 mg twice daily.
Weight loss at 12 weeks was 3.3%, 6.7%, and
7.2% in the lorcaserin only and the
combination with phentermine once or twice
daily, respectively.
Analysis of the food craving data evaluated
using the FCI indicated that subjects in all
treatment groups showed improvement in the
FCI total score from baseline to week 12 as well
as in the FCI subscale scores for high-fat foods,
sweets, carbohydrates, and fast foods without
any one particular category of foods driving the
overall effect [52]. Subjects also reported
improvements in control of eating in all
treatment groups at week 12 compared to
baseline, evaluated using the COEQ. The
frequency and strength of food cravings
reduced including the craving for chocolate,
sweets, non-sweets, and starchy foods in a
sample that comprised 85% women. The
limitation of this study is that there was no
placebo-treated group [53].
In the brains of humans GLP-1 receptors have
been identified in the hypothalamus, medulla,
and parietal cortex [82]. In human subjects, the
GLP-1 receptor agonist exenatide reduced
activation in response to food cues in brain
areas involved in the regulation of reward, the
effect of which was greatly attenuated by GLP-1
receptor blockade [83, 84]. The response toGLP-1
receptor blockade was more pronounced in
subjects with type 2 diabetes and obesity than
in lean healthy subjects [85]. In response to
treatment for 17 days with liraglutide
(SaxendaTM) a GLP-1 agonist approved by the
FDA for long-treatmentof obesity [86], activity in
the parietal cortex decreased when subjects
viewed images of highly desirable foods
compared to placebo. The parietal cortex is
involved in controlling the location of
attention [87]; hence, it is likely that there was
a reducedappeal of the food cues, especially since
liraglutide treatment also increased fullness and
reduced food intake [82]. However, gastric
inhibitory peptide increased and serum leptin
decreased in response to food cues, eachofwhich
has opposing effects in the areas of the brain
involved with rewardmechanisms [88]. Leptin is
secreted by fat cells and binds to specific leptin
receptors on dopaminergic neurons in the
ventral tegmental area to inhibit dopamine
signaling in the nucleus acumbens and
amygdala. Unlike gastric inhibitory peptide,
leptin reduces reward-related eating behavior
[89]. The short-term effects of liraglutide on
reward mechanisms warrant corroboration in
future studies.
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Food-Based Interventions
Thylakoids are compartments inside the
chloroplasts of green plants such as spinach
and are composed of membranes that form the
internal photosynthetic membrane system of
chloroplasts. By interacting with lipids and
delaying fat digestion, thylakoid membranes
promote the release of hormones that mediate
satiety [90]. Studies investigating the effects of
thylakoids (AppethylTM) on eating behavior
have demonstrated increases in perceptions of
satiety [91, 92], and a reduction in body weight
[93]. Additionally, two studies demonstrated a
decrease in the craving for sweet foods and
chocolate among women in the overweight or
obese body mass index range, measured
subjectively [93, 94]. In another study, men
tended to reduce their intake at a pizza meal;
whereas, among women food intake did not
change following a 5-g dose of thylakoids [91].
Men and women tend to crave different kinds of
foods, have different experiences of craving,
and differ in their responses. Men report a
craving for savory foods, and a
disproportionately large percentage of those
who experience a craving for chocolate are
women [29]. The gender differences
demonstrated by studies investigating the
effects of thylakoids suggest that thylakoids
may influence the reward system.
CONCLUSIONS
Neural systems, located primarily in the
brainstem and hypothalamus, represent the
homeostatic regulators of food intake;
whereas, the neural pathways and functions
located in the corticolimbic structures are
responsible for reward-related control of eating
[38]. Nevertheless, hypothalamic signals
regulating energy intake can influence the
activity of the hedonic or reward systems in
the corticolimbic structures [38]. Similarly,
signals generated in the corticolimbic
structures processing sensory, cognitive, and
reward information can modulate
hypothalamic processes involved in
homeostatic control [39]. Although the
balance between energy intake and
expenditure is controlled by a powerful
unconscious biological system, the laws of
thermodynamics predict that body weight can
be controlled by consciously balancing food
intake and energy expenditure. If being able to
control food cravings is a determinant of
success at adhering to a diet regimen then
addressing cravings may be particularly relevant
to people with obesity. Therefore, anti-obesity
medications that reduce reward-induced eating
behavior can be especially helpful in
overcoming strong desires to eat.
Lorcaserin and the combination of
naltrexone and bupropion, which are both
approved by the FDA for long-term weight
management, have shown promise in
addressing craving-related eating behavior.
Phentermine and liraglutide are approved as
monotherapies for weight management.
Preliminary research suggests that liraglutide,
as well as phentermine alone or in combination
with lorcaserin may be effective in targeting
food cravings. Food components such as
thylakoid membranes have also been shown to
influence food cravings. Strategies that
effectively target food cravings can facilitate
weight loss and maintenance leading to
long-term improvements in obesity-related
comorbidities. Thus, it is important that
clinicians are aware of options to address the
reward components of eating behavior that may
be used in conjunction with lifestyle change
efforts, when appropriate.
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